KR102626626B1 - Ache의 t14 펩타이드를 인식하는 항체 - Google Patents
Ache의 t14 펩타이드를 인식하는 항체 Download PDFInfo
- Publication number
- KR102626626B1 KR102626626B1 KR1020177027589A KR20177027589A KR102626626B1 KR 102626626 B1 KR102626626 B1 KR 102626626B1 KR 1020177027589 A KR1020177027589 A KR 1020177027589A KR 20177027589 A KR20177027589 A KR 20177027589A KR 102626626 B1 KR102626626 B1 KR 102626626B1
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- antigen
- delete delete
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505239.2A GB201505239D0 (en) | 2015-03-27 | 2015-03-27 | Antibody |
| GB1505239.2 | 2015-03-27 | ||
| GB1600871.6 | 2016-01-18 | ||
| GB1600871.6A GB2541477A (en) | 2015-03-27 | 2016-01-18 | Antibody |
| PCT/GB2016/050804 WO2016156803A1 (en) | 2015-03-27 | 2016-03-23 | Antibody that recognises the t14 peptide of ache |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170138414A KR20170138414A (ko) | 2017-12-15 |
| KR102626626B1 true KR102626626B1 (ko) | 2024-01-17 |
Family
ID=53178191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177027589A Active KR102626626B1 (ko) | 2015-03-27 | 2016-03-23 | Ache의 t14 펩타이드를 인식하는 항체 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10954306B2 (https=) |
| EP (1) | EP3274371B1 (https=) |
| JP (1) | JP7327897B2 (https=) |
| KR (1) | KR102626626B1 (https=) |
| CN (1) | CN107531796A (https=) |
| AU (1) | AU2016240020B2 (https=) |
| BR (1) | BR112017020769A2 (https=) |
| CA (1) | CA2979972A1 (https=) |
| ES (1) | ES2952723T3 (https=) |
| GB (2) | GB201505239D0 (https=) |
| MX (1) | MX392158B (https=) |
| RU (1) | RU2729491C2 (https=) |
| WO (1) | WO2016156803A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2539161A (en) * | 2014-11-26 | 2016-12-14 | Neuro-Bio Ltd | Neurodegenerative disorders |
| GB2546773B (en) * | 2016-01-28 | 2020-06-17 | Neuro Bio Ltd | Cancer |
| GB201705044D0 (en) * | 2017-03-29 | 2017-05-10 | Neuro-Bio Ltd | Biomarker |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| GB202112831D0 (en) * | 2021-09-09 | 2021-10-27 | Neuro Bio Ltd | Biomarker |
| GB202113941D0 (en) | 2021-09-29 | 2021-11-10 | Neuro Bio Ltd | Skin biomarker |
| CN120187864A (zh) | 2022-09-08 | 2025-06-20 | 神经生物有限公司 | 使用t14肽诊断阿尔茨海默症的侧向流装置 |
| GB202308779D0 (en) * | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Aptamer |
| GB202308799D0 (en) | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Neurodegenerative disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035962A1 (en) | 1996-03-22 | 1997-10-02 | Synaptica Limited | Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1269201A1 (en) | 2000-03-29 | 2003-01-02 | Synaptica Limited | Alpha 7 nicotinic receptor screening assays |
| GB0028578D0 (en) * | 2000-11-23 | 2001-01-10 | Synaptica Ltd | Screening assays |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
| JP5186372B2 (ja) * | 2005-08-16 | 2013-04-17 | ジェネンテック， インコーポレイテッド | 細胞／組織においてｇａｌｎａｃ−ｔ１４発現を試験することによるａｐｏ２ｌ／ｔｒａｉｌに対するアポトーシス感受性 |
| GB0708646D0 (en) * | 2007-05-04 | 2007-06-13 | Enkephala Ltd | Biologically active C-terminal fragment of acetylcholinesterase |
| EP2203746B1 (en) * | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| CN101530162B (zh) * | 2008-03-10 | 2011-11-23 | 北京大北农科技集团股份有限公司 | 一种新型蛋白饲料添加剂的制备方法 |
-
2015
- 2015-03-27 GB GBGB1505239.2A patent/GB201505239D0/en not_active Ceased
-
2016
- 2016-01-18 GB GB1600871.6A patent/GB2541477A/en not_active Withdrawn
- 2016-03-23 RU RU2017133649A patent/RU2729491C2/ru active
- 2016-03-23 MX MX2017012397A patent/MX392158B/es unknown
- 2016-03-23 US US15/561,021 patent/US10954306B2/en active Active
- 2016-03-23 CA CA2979972A patent/CA2979972A1/en active Pending
- 2016-03-23 BR BR112017020769-9A patent/BR112017020769A2/en active Search and Examination
- 2016-03-23 AU AU2016240020A patent/AU2016240020B2/en not_active Ceased
- 2016-03-23 WO PCT/GB2016/050804 patent/WO2016156803A1/en not_active Ceased
- 2016-03-23 JP JP2017550514A patent/JP7327897B2/ja active Active
- 2016-03-23 EP EP16713029.3A patent/EP3274371B1/en active Active
- 2016-03-23 CN CN201680021081.0A patent/CN107531796A/zh active Pending
- 2016-03-23 ES ES16713029T patent/ES2952723T3/es active Active
- 2016-03-23 KR KR1020177027589A patent/KR102626626B1/ko active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035962A1 (en) | 1996-03-22 | 1997-10-02 | Synaptica Limited | Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
| JP2000509967A (ja) * | 1996-03-22 | 2000-08-08 | シナプティカ リミテッド | カルシウムチャンネルモジュレーターとして活性のあるアセチルコリンエステラーゼの可溶形態からのペプチド |
Non-Patent Citations (1)
| Title |
|---|
| Cottingham M. et al, Biochemistry 42:pp.10863~10873 (2003)* |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201505239D0 (en) | 2015-05-13 |
| CN107531796A (zh) | 2018-01-02 |
| US20180051094A1 (en) | 2018-02-22 |
| US10954306B2 (en) | 2021-03-23 |
| EP3274371B1 (en) | 2023-06-07 |
| AU2016240020A1 (en) | 2017-11-02 |
| CA2979972A1 (en) | 2016-10-06 |
| ES2952723T3 (es) | 2023-11-03 |
| JP7327897B2 (ja) | 2023-08-16 |
| WO2016156803A1 (en) | 2016-10-06 |
| MX392158B (es) | 2025-03-21 |
| AU2016240020B2 (en) | 2022-02-17 |
| BR112017020769A2 (en) | 2018-06-26 |
| GB201600871D0 (en) | 2016-03-02 |
| RU2729491C2 (ru) | 2020-08-07 |
| GB2541477A (en) | 2017-02-22 |
| MX2017012397A (es) | 2018-01-26 |
| RU2017133649A3 (https=) | 2020-02-17 |
| JP2018516849A (ja) | 2018-06-28 |
| EP3274371A1 (en) | 2018-01-31 |
| RU2017133649A (ru) | 2019-04-29 |
| KR20170138414A (ko) | 2017-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102626626B1 (ko) | Ache의 t14 펩타이드를 인식하는 항체 | |
| US11739140B2 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| JP7244600B2 (ja) | 過リン酸化タウに特異的な抗体およびその使用方法 | |
| JP6124591B2 (ja) | タウオリゴマーに結合する抗体 | |
| JP6517156B2 (ja) | 抗トランスサイレチンヒト抗体 | |
| TW201716440A (zh) | 用於治療共核蛋白病的藥劑、用途及方法 | |
| JPWO2020032027A1 (ja) | アルツハイマー病の判定薬および判定方法 | |
| Roßner et al. | Identification of a novel Aβ (pGlu3-x) targeting pathway in Alzheimer’s disease | |
| HK40059227A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| EA039569B1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения | |
| HK40007700A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| HK40007700B (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| HK1164330A (en) | AMYLOID-β(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170928 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210322 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230419 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20231030 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240115 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240115 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |